Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Btg International Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner within 1 distinct art unit. This concentration indicates that the company's current prosecution activity is highly localized, with all pending matters residing in a single administrative channel.
The busiest examiner for this portfolio is HAVLIN, ROBERT H, who is currently managing the 1 pending office action. Because there is only 1 distinct examiner and 1 distinct art unit involved, the company's immediate strategy in the Biotechnology & Pharmaceuticals sector is focused on the requirements set by HAVLIN, ROBERT H. The lack of multiple pending actions simplifies the tracking of deadlines and examiner-specific preferences.
With 1 pending office action assigned to HAVLIN, ROBERT H, the company's current patent office footprint is limited to this interaction. The 1 distinct art unit involved provides a consistent regulatory framework for this specific matter. This profile, featuring 1 pending office action and 1 distinct examiner, reflects a streamlined prosecution state for Btg International Inc. at this time.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260779 | SUBCUTANEOUS OR INTRAMUSCULAR INJECTION FORMULATIONS OF ILOPROST | HAVLIN, ROBERT H | 105d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260779 | SUBCUTANEOUS OR INTRAMUSCULAR INJECTION FORMULATIONS OF ILOPROST | HAVLIN, ROBERT H | 105d overdue |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260779 | SUBCUTANEOUS OR INTRAMUSCULAR INJECTION FORMULATIONS OF ILOPROST | HAVLIN, ROBERT H | 1626 | §102§103 | Final Rejection | 105d overdue | Pending | Jul 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial